Loading clinical trials...
Loading clinical trials...
Women With Epilepsy: a Pilot Study of Pharmacokinetic and Pharmacodynamic Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users
The investigators will conduct a prospective, seven-month pilot study to explore pharmacokinetic (PK) and pharmacodynamic (PD) effects among women with epilepsy using the levonorgestrel intrauterine system (LNG IUS) for contraception. The investigators will enroll twenty women with well-controlled epilepsy maintained on stable anti-epileptic drugs (AED) therapy seeking the LNG IUS for contraception. The primary outcomes are AED levels and seizures before and after LNG IUS placement. Secondary outcomes include LNG levels, evidence of ovulation three weeks after insertion (serum progesterone \>3ng/ml), bleeding and spotting, endometrial thickness, continuation, satisfaction and adverse events (removals, expulsions, side effects). The investigators will conduct a baseline month assessment, insertion visit, and follow-up visits at 21 days, three months and six months.
Study Procedures This pilot study consists of five study visits. Once preliminary eligibility is determined through a telephone screening interview, the first visit is scheduled. Visit 1 Enrollment/Baseline * Review Eligibility * Informed Consent * Collect Baseline Information * Vital Signs * Pregnancy Test * Complete Physical Exam including Pelvic exam, * Chlamydia testing, and a Pap test if needed as per ASCCP (American Society for Colposcopy and Cervical Pathology) guidelines * Receive diary to record any bleeding or spotting * Receive condoms, if needed, for use until IUS insertion * Sign release for contact of primary neurologist or epileptologist * Study MD to contact participant's neurologist to notify of trial participation, and verify type and dose of AEDs Visit 2 Insertion/4-6 Weeks from Baseline * Vital Signs * Pregnancy Test * Phlebotomy for hormone and AED levels * Transvaginal ultrasound * IUS Insertion * Review and collect completed diary * Receive new diary Visit 3/ Follow up 3 Weeks post IUS Insertion * Vital Signs * Phlebotomy for hormone and AED levels * Transvaginal Ultrasound * Review and collect completed diary * Receive new diary Visit 4/Follow up 3 Months post IUS Insertion * Vital Signs * Phlebotomy for hormone and AED levels * Transvaginal ultrasound * Review and collect completed diary * Receive new diary * Acceptability Questionnaire Visit 5/ Exit 6 Months post IUS insertion * Vital Signs * Phlebotomy for hormone and AED levels * Transvaginal Ultrasound * Review and collect final completed diary * Acceptability Questionnaire
Age
18 - 45 years
Sex
FEMALE
Healthy Volunteers
No
Columbia University
New York, New York, United States
Start Date
August 1, 2011
Primary Completion Date
January 1, 2014
Completion Date
January 1, 2014
Last Updated
January 18, 2016
20
ACTUAL participants
levonorgestrel IUS
DRUG
Lead Sponsor
Columbia University
Collaborators
NCT06700356
NCT06345586
NCT02531880
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions